Latest Caris Life Sciences Stories
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
Results, Published in Clinical Genitourinary Cancer, Offer Key Insights and Potential New Treatment Strategies for Patient Population with Limited Drug Options IRVING, Texas, Oct.
IBM Technical Computing & Software Defined Storage Technology Manages Growing Scale and Diversity of Molecular Profiling Data in Cancer Care ARMONK, N.Y., Sept.
IRVING, Texas, Aug.
Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug.
IRVING, Texas, June 24, 2014 /PRNewswire/ -- Valley Medical Oncology Consultants (VMOC) and Caris Life Sciences announced today a collaboration to establish a clinical molecular profiling program
Median Overall Survival was 8 Years Longer for Women who were Treated with Therapies Consistent with Caris Molecular Intelligence(TM) Tumor Profiling Prediction and was 2 ½ years Longer after Recurrence IRVING,
Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused
Combined Gene and Protein Analysis of Sarcoma Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 2, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading
Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading
- Withering but not falling off, as a blossom that persists on a twig after flowering.